Literature DB >> 26456751

Definition, Classification, and Pathophysiology of Canine Glaucoma.

Stefano Pizzirani1.   

Abstract

Glaucoma is a common ocular condition in humans and dogs leading to optic nerve degeneration and irreversible blindness. Primary glaucoma is a group of spontaneous heterogeneous diseases. Multiple factors are involved in its pathogenesis and these factors vary across human ethnic groups and canine breeds, so the clinical phenotypes are numerous and their classification can be challenging and remain superficial. Aging and oxidative stress are major triggers for the manifestation of disease. Multiple, intertwined inflammatory and biochemical cascades eventually alter cellular and extracellular physiology in the optic nerve and trabecular meshwork and lead to vision loss.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Canine; Closed angle; Glaucoma; Goniodysgenesis; Open angle; Primary glaucoma; Secondary glaucoma

Mesh:

Year:  2015        PMID: 26456751     DOI: 10.1016/j.cvsm.2015.06.002

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  3 in total

Review 1.  Biomechanical aspects of axonal damage in glaucoma: A brief review.

Authors:  Cheri Stowell; Claude F Burgoyne; Ernst R Tamm; C Ross Ethier
Journal:  Exp Eye Res       Date:  2017-02-20       Impact factor: 3.467

2.  Effects of topical administration of tafluprost and combination of tafluprost and timolol or tafluprost and betaxolol on Schirmer tear test, intraocular pressure, and pupil size in clinically healthy dogs.

Authors:  Armin Shokoohimand; Farnoosh Arfaee; Ahmad Asghari; Ehsan Khaksar
Journal:  Int Ophthalmol       Date:  2020-06-05       Impact factor: 2.031

3.  Primary closed angle glaucoma in the Basset Hound: Genetic investigations using genome-wide association and RNA sequencing strategies.

Authors:  James A C Oliver; Sally L Ricketts; Markus H Kuehn; Cathryn S Mellersh
Journal:  Mol Vis       Date:  2019-02-08       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.